Evaluating the difference in clinical efficacy for t(11;14) multiple myeloma patients with CD20- or CD20+

Evaluating the difference in clinical efficacy for t(11;14) multiple myeloma patients with CD20- or CD20+

Objective To examine the differences in therapy response and confirm the effective regimen for multiple myeloma (MM) patients with t (11; 14)/CD20- or CD20+, for the selection of transplantation as early treatment. Methods To find the differences in therapy response and to confirm the effective regi...

Full description

Bibliographic Details
Main Author:	ZHAO Weihong, HUANG Bintao, LIU Rui, XIANG Caixia
Format:	Article
Language:	zho
Published:	Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. 2023-09-01
Series:	Jichu yixue yu linchuang
Subjects:	multiple myeloma\|t(11;14)\|bortezomib\|lenalidomide
Online Access:	http://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2023-43-9-1423.pdf

Similar Items

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
by: Yuan Jian, et al.
Published: (2022-12-01)

The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
by: Kenneth JC Lim, et al.
Published: (2023-08-01)

Prevalence of the t(11; 14)(q13; q32) immunoglobulin H/CCND1 in Mexican mestizos with multiple myeloma: A single institution experience
by: Olivia Lira-Lara, et al.
Published: (2024-02-01)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
by: Michael D. Diamantidis, et al.
Published: (2022-08-01)

Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review
by: Hesham Elsabah, et al.
Published: (2024-07-01)

Advances in multiple myeloma therapy during two past decades
by: Ivan Spicka
Published: (2014-06-01)

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients
by: Yuka Kawaji‐Kanayama, et al.
Published: (2022-02-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

How I manage frontline transplant-eligible multiple myeloma in Italy
by: Vittorio Montefusco, et al.
Published: (2020-09-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma
by: Alpay Yeşilaltay, et al.
Published: (2024-01-01)

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
by: Panagiotis Samaras, et al.
Published: (2015-02-01)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
by: Pınar Ataca Atilla, et al.
Published: (2019-11-01)

New drugs in the therapy of multiple myeloma Novas drogas na terapia do mieloma múltiplo
by: Antonio Palumbo, et al.
Published: (2008-06-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations
by: C Taverna, et al.
Published: (2010-09-01)

Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations
by: Swiss Medical Weekly
Published: (2010-04-01)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
by: Liang Zhou
Published: (2022-03-01)

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States
by: Rohan Medhekar, et al.
Published: (2022-08-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
by: Dong Liang, et al.
Published: (2024-09-01)

SIL-TAL1-Positive Adult T-ALL with t(11;14)(p15;q11.2): A Rare Case Report Highlighting Prognostic Challenges and Treatment Implications
by: Chen S, et al.
Published: (2025-02-01)

Selective purging of human multiple myeloma cells from peripheral blood mononuclear cells: a preliminary study
by: Lee AJ, et al.
Published: (2019-04-01)

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
by: Khadega A. Abuelgasim, et al.
Published: (2020-04-01)

Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective
by: Lineo Marie Matsela, et al.
Published: (2022-12-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects
by: Abdullah AlZahrani, et al.
Published: (2024-12-01)

A feline case of multiple myeloma treated with bortezomib
by: Hiroyuki Tani, et al.
Published: (2022-11-01)

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
by: Shu-Kai Qiao, et al.
Published: (2015-01-01)

Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
by: Sinan Mersin, et al.
Published: (2021-08-01)

Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
by: Yaman Alali, et al.
Published: (2021-12-01)

A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan
by: Shang-Yi Huang, et al.
Published: (2017-09-01)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
by: Maryam Pourabdollah, et al.
Published: (2016-11-01)